The serotonin transporter is a sodium and chloride-coupled transporter that "pumps" extracellular serotonin into cells. S-citalopram is a drug used to treat depression and anxiety by binding to the serotonin transporter with high-affinity, blocking serotonin reuptake. Here we report an efficient procedure and a set of tools to stabilize, express, purify, and crystallize serotonin transporter-antibody complexes bound to S-citalopram and other antidepressants. Mutations which stabilize the serotonin transporter were identified using an S-citalopram binding assay. Serotonin transporter expressed in baculovirus-transduced HEK293S GnTI cells, was reconstituted into proteoliposomes and used to raise high-affinity antibodies. We have developed a strategy to discover antibodies that are useful for structural studies. A straightforward approach for the expression of antibody fragments in Sf9 cells has also been established. Transporter-antibody complexes purified using this procedure are wellbehaved and readily crystallize, producing complexes with S-citalopram that diffract X-rays to 3-4 Å resolution. The strategies developed here can be utilized to determine the structure of other challenging membrane proteins.
Introduction
The serotonin transporter (SERT) is an integral membrane protein that facilitates the transport of serotonin across cellular membranes 1 . SERT belongs to a family of Neurotransmitter Sodium Symporters (NSSs) which also includes the dopamine and norepinephrine transporters 2 . SERT is the molecular target of widely prescribed antidepressant and anti-anxiety drugs which act to competitively inhibit serotonin transport 3 . SERT exploits the energetically favorable cotransport of sodium to remove neurotransmitter from the synaptic cleft. Extensive characterization of the serotonergic system has shown that changes in serotonin metabolism appear to influence virtually all neurological processes including mood, sleep, pain, cognition, and aggression behaviors 4 . SERT function can be modified through the use of antidepressants and Selective Serotonin Reuptake Inhibitors (SSRIs) like S-citalopram, as well as by psychostimulants and drugs of addiction such as amphetamine and 3,4methylenedioxy-N-methylamphetamine or "ecstasy" 1, 2 . SSRIs are tremendously important for the treatment of mood disorders, yet the precise structural basis for their action is not well understood. WT SERT is unstable in detergent micelles, thus impeding progress towards a three-dimensional (3D) structure of SERT P2 virus per 800 mL of cells in a 2 L baffled flask. NOTE: It is not recommended to use more than 80 mL of P2 virus since the HEK293S GnTI cells will grow slowly and may become unviable due to a change in pH. Sf9 media is more acidic than the 293 expression media. 8. 12 -16 h post-infection, add sodium butyrate to a concentration of 10 mM from a 1 M stock. 48 -60 h post-infection, harvest cells by centrifugation at 4,000 x g for 15 min. Remove the supernatant. 9. Resuspend cells in 150 mL of TBS, 2 µM S-citalopram or other SERT inhibitors and store at -80 °C until ready for purification.
Affinity Purification of the Serotonin Transporter for Immunization and Crystallization
1. Thaw cells from 10 L of culture in warm water (approximately 30 °C) and resuspend by rapidly passing through a 10 mL pipette until homogeneous. 2. Prepare detergent solution for solubilization (150 mL): 80 mM Tris, pH 8, 150 mM NaCl containing 40 mM C12M, 5 mM CHS, and protease inhibitor cocktail. 3. Add all of the cells to a beaker with a stir bar and add all of the detergent solution to the cells while stirring. Solubilize at 4 °C for 1 h with stirring. 4. Spin lysate at 8,000 x g for 15 min at 4 °C. Discard pellet and decant supernatant into clean ultracentrifuge tubes. Spin at 100,000 x g for 1 h in an ultracentrifuge. Discard pellet and filter supernatant through a 0.2 µm filter. 5. Pass lysate over 10 mL of Strep affinity resin packed into a column using a peristaltic pump equilibrated in wash buffer: 1 mM C12M, 0.2 mM CHS, 5% glycerol, 25 µM lipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol at a molar ratio of 1:1:1), and 1 µM S-citalopram or SSRI in TBS. 6. Connect Strep affinity column to a Fast Protein Liquid Chromatography (FPLC) system and wash column at 2 mL/min with 66 mL (6.6 column volumes) of wash buffer. Elute purified protein in same buffer supplemented with 5 mM desthiobiotin at 0.5 mL/min using 33 mL (3.3 column volumes) of buffer. Collect 1 mL fractions; the peak fractions will be ~10 mL. Purified protein may be stored at 4 °C for 2 -3 d if desired. NOTE: Total yield will be 3 -4 mg of SERT CC and 1 mg of SERT IC . An absorbance of 2 AU at 280 nm is equal to 1 mg/mL SERT. suspension. 6. Extrude the entire lipid mixture twice through 200 nm filters. The lipid will appear as a milky suspension prior to extrusion; afterward it will be translucent. Do not add the entire lipid mixture to the extruder at once as it can become clogged, resulting in loss of sample.
Reconstitution of Transporter into Liposomes for Immunization

Representative Results
A library of single point mutants in the SERT TC background was created to screen for thermostabilizing mutations. Individual mutants were generated using standard mutagenesis. The screening protocol utilizes transiently transfected HEK293S cells and a scintillation proximitybased thermostability screen to rapidly identity useful mutations for crystallization as outlined in Figure 1A . Plotting Tm values versus bound [ 3 H]citalopram at RT reveals constructs with high thermostability and expression levels suitable for protein purification (Figure 1B) . Three mutants (Y110A, I291A, and T439S) were combined to generate a highly stable construct ( Figure 1C ). Thermostability is also correlated with increased stability in short chain detergents necessary for the crystallization of the SERT-Fab complex.
The large scale expression of human SERT using baculovirus-transduced HEK293S GnTI cells can take less than 2 weeks and can produce milligram quantities, as illustrated in Figure 2A . Use of the GFP-tagged SERT CC protein allows SERT to be conveniently followed during expression and purification by fluorescence ( Figure 2B) . Our purification strategy involved 1) solubilization of SERT bound to S-citalopram from HEK293S GnTI cells in C12M in the presence of CHS as a stabilizing lipid; 2) binding of SERT to a Strep affinity matrix; 3) removal of . Multilamellar liposomes were prepared by the addition of buffer to a dried lipid mixture in glass tubes and resuspended in buffer. Extrusion of the liposomes through 200 nm pore size filters produces monodisperse unilamellar liposomal suspensions. The liposomes are then saturated with detergent followed by the addition of purified SERT in detergent. Finally, detergent is removed by addition of hydrophobic absorption resin to the lipid:detergent mixture. Additional ligand should be added to the reconstituted sample to select for antibodies that recognize the antidepressant bound conformation. The presence of SERT in the proteoliposomes should be confirmed by solubilizing a small sample with SDS-PAGE loading dye or C12M and running on SDS-PAGE and FSEC (Figure 3C, D) .
Hybridoma cell lines expressing SERT antibodies can be screened for high-affinity binders which recognize 3D epitopes. These properties are crucial to the eventual success of crystallization, as the antibody must remain firmly bound to a structured region to promote crystal packing of homogeneous, well-ordered domains. In the first step, antibodies which recognize unstructured regions are identified. SERT is denatured and blotted onto a nitrocellulose membrane; antibodies which bind denatured SERT will be western-positive and likely recognize linear epitopes. In Figure 4A , we show 2 examples of antibodies which are western-positive and likely not useful to promote crystallogenesis. In Figure 4B , the remaining western-negative antibodies are incubated with 100 nM SERT-GFP and separated by FSEC. Antibodies which bind SERT will shift the GFP-positive peak to an earlier position. The SERT-antibody complexes may be diluted further in detergent to determine if they can bind with nanomolar affinity followed by analysis by FSEC. Addition of serotonin results in conformational changes in the transporter and thus the antibodies can be rescreened to determine if they can specifically recognize the SSRI-bound conformation. In Figure 4C , the antibodies are shown to bind SERT in the presence of serotonin, showing that the epitope(s) do not change from the SSRI to substrate bound state. Finally, in Figure 4D combinations of antibodies are tested for their ability to bind distinct epitopes, resulting in a further leftward shift. Here the 15B8 or 8A11 antibodies recognize an epitope which is different from 8B6.
The 8B6 antibody was chosen for further structural analysis based on preliminary crystal screening with papain treated Fab. The genes of the 8B6 Fab were cloned into an insect cell expression vector. Fab can be expressed and secreted from Sf9 cells growing in suspension. The 8B6 Fab can be purified from Sf9 cell supernatant by His-tag affinity (Figure 5A, B) and cation exchange chromatography (Figure 5C, D) resulting in protein which appears free of contaminants on SDS-PAGE gels. In Figure 5E , the recombinant 8B6 Fab is shown to bind SERT and is used in subsequent biochemical and biophysical experiments. 
Discussion
Determination of membrane protein structure by biophysical techniques remains a daunting undertaking for many medically significant transporters, receptors, and channels 11 . Here we share detailed expertise developed for the structure determination of the human serotonin transporter bound to S-citalopram. We anticipate that these methods will be useful to determine structures of SERT in other conformational states as well as structures of other difficult membrane proteins. Furthermore, the biochemical techniques described here can also be used to study function of purified SERT in detergent and a near-native lipid environment. SERT crystallization hinged upon the development of several tools and techniques. First, improvements in transporter thermostability produced SERT variants which were well-behaved in various detergent micelles following extraction of the transporter from membranes 6 . Second, the use of the high-affinity ligand S-citalopram throughout purification and crystallization further improved stability and reduced conformational heterogeneity. Third, the development of the BacMam expression system 7 allowed for production of large amounts of SERT in a short period of 2 weeks, facilitating both immunization and crystallization. Finally, the development of strategies to select for high-affinity antibodies which recognize 3D epitopes allowed for the discovery of the 8B6 antibody which promotes well-ordered packing of SERT-antibody complexes into crystals.
There are a number of critical steps and reagents as well as common problems which often occur throughout the protocol. First, the generation of high titer SERT P2 virus can be problematic. Adding low concentrations of P1 virus to generate P2 virus as described in this protocol usually mitigates this problem, and in cases where the P2 virus titer is low, P3 virus can be made using virus at an MOI of 0.0001. Viruses with a titer less than 1 x 10 8 virus particles/mL should not be used and will almost always result in low protein yields. For expression, HEK293S GnTI cells were chosen since they lack N-acetylglucosaminyltransferase I activity and thus cannot synthesize complex N-glycans, instead producing only high mannose N-glycans. EndoH cleaves N-linked glycosylation of high mannose glycans at two sites in extracellular loop 2 (EL2), leaving an N-acetylglucosamine attached to asparagine. Digestion of N-linked sugars reduces surface entropy of EL2 which is likely important for crystallization. For the generation of antibodies, the SERT IC should be used for immunization. GFP is highly immunogenic 12 and should not be used as a fusion tag to generate antibodies since it is difficult to completely remove by SEC. The flexible N-and C-terminus of SERT were also not included in the construct in order to avoid antibodies against these regions. Mice can be immunized with 30 µg of reconstituted protein; continue immunizing mice until high serum concentrations of antibodies can be detected and produce hybridoma cells as described 13 . A thermostabilized construct is usually the best choice for immunization; if the transporter is well behaved and retains biological activity following purification, this is often sufficient to raise antibodies. The 8B6 antibody was raised against WT SERT. For crystallization, only the peak fractions from SEC containing monodisperse complex as judged by FSEC should be combined and concentrated. SERT-8B6 crystals grow in a narrow range of conditions and there are a number of steps which should be taken to troubleshoot problems specifically related to SERT crystal growth. Tris base adjusted with HCl should not be used in the reservoir solution, since this buffer does not support crystal growth; it is thus critical to instead use Tris adjusted with NaOH. SERT crystals grow in a narrow concentration range of PEG 400, so if crystals do not grow or if many small crystals are observed, even a small increase or decrease in the PEG 400 concentration would be advised. Furthermore, the additive 6aminohexanoic acid was also used in the optimized screen to improve nucleation. The drop ratio of protein:well solution is also a key determining factor for crystal growth. Drop ratios of 1.5 -2:1 are recommended, with drop ratios closer to 2:1 typically supporting the growth of larger 3dimensional crystals. Finally, the use of low profile 24-well plates is also crucial toward crystal growth, presumably due to modification of the rate of vapor diffusion.
An alternative approach to the SPA method has been developed to screen for mutants which stabilize the rat serotonin transporter in a cocaine-bound conformation using a filter binding assay 5 . By contrast, the SPA based assay allows for sequential heating steps following by determination of the fraction of SERT which remains bound to ligand. Thus, this allows for the rapid determination of the melting temperature from a small number of samples. The SPA method relies on the availability of a radiolabeled high-affinity ligand and if no ligands are known which bind with submicromolar affinity then an alternative approach will be necessary. Many other methods are commonly used to measure protein stability such as binding of fluorescent dyes and calorimetry 14 but are low-throughput and are either unable to directly measure function or require large amounts of protein. If the SPA method cannot be used, one alternative high-throughput approach is an FSEC-based Thermostability Assay 15 (FSEC-TS), where the sample is heated followed by separation of the fraction of remaining transporter. FSEC-TS is a useful approach for accessing chromatographic behavior and oligomeric state and is a powerful complementary tool which can be used alongside the SPA method.
A comparison of various common protein expression systems was also found to favor the use of mammalian cells for SERT expression 16 and unsurprisingly this is likely the case for many proteins of mammalian origin. The methods which we have used for expression have been tailored for SERT but are likely readily adaptable. Conditions which favor high levels of expression should be carefully identified by varying the time of expression, temperature, virus concentration, and presence of histone deacetylase inhibitors such as sodium butyrate.
We generally favor affinity purification in a mild long-chain detergent such as C12M together with CHS prior to reconstitution to retain highaffinity ligand binding. Reconstitution using hydrophobic absorption is a mild technique which we have found to be effective for several other transporters and receptors. If this is not successful, removal of detergents with high critical micelle concentrations by dialysis, dilution, or SEC can be employed 17 provided the antigen is sufficiently stable in such detergents. In cases where no suitable antibodies are found, we almost always find the issue is due to loss of function or denaturation of the antigen and in such cases we successfully performed new immunizations paying special attention to protein biochemistry. Finally, ligands and antibodies which bind with high-affinity should form the basis for a rationally planned crystallization experiment and by taking advantage of a thermostable variant, one can screen a broader range of conditions by varying the properties of different detergents. Furthermore, crystallization in a lipidic mesophase 18 or using bicelles 19 should always be considered as an alternative to crystallization in micelles.
These principals and methods can be used with some modification for many other transmembrane proteins which are difficult to express and purify from other expression hosts, and will be particularly useful for the structure determination of targets of high-affinity drugs.
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